Body shape and metabolic abnormalities in Thai HIV-infected patients

AIDS Research and Human Retroviruses

Volumn 23, Issue 11, 2007, Pages 1314-1321

  Homsanit, Mayuree ^a,d   Nelson, Kenrad E ^b   Sonjai, Areeuea ^a   Anekthananon, Thanomsak ^a   Suwanagool, Surapol ^a   Cofrancesco Jr , Joseph ^c  

^a MAHIDOL UNIVERSITY   (Thailand)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR; DIDANOSINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDINAVIR; LAMIVUDINE; LOPINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; TRIACYLGLYCEROL; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; LIPID;

ABDOMINAL FAT; ADULT; ARTICLE; BODY BUILD; BODY COMPOSITION; BODY FAT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED STUDY; DUAL ENERGY X RAY ABSORPTIOMETRY; EDUCATIONAL STATUS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; LIPID METABOLISM; LIPID STORAGE; LIPOATROPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; PREVALENCE; PRIORITY JOURNAL; SEX DIFFERENCE; SINGLE BLIND PROCEDURE; SOCIAL STATUS; THAILAND; TRIACYLGLYCEROL BLOOD LEVEL; ADIPOSE TISSUE; BLOOD; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; PATHOLOGY; PHOTON ABSORPTIOMETRY; RADIOGRAPHY;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; LIPIDS; MALE; METABOLIC DISEASES; MIDDLE AGED; PREVALENCE; THAILAND;

EID: 38449119471     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2007.0013     Document Type: Article

References (29)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998;338:853-860.
2. Miller KK, Daly PA, Sentochnik JD, et al.: Pseudocushing's syndrome in human immunodeficiency virus infected patients. Clin Infect Dis 1998;27:68-72.
3. Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV-1-protease inhibitors. AIDS 1998;12:F51-58.
4. Christeff N, Melchior JC, de Truchis P, et al.: Lipodystrophy defined by clinical score in HIV-infected men on highly active antiretroviral therapy: Correlation between dyslipidemia and steroid hormone alteration. AIDS 1999;13:2251-2260.
5. Mulligan K, Grunfield C, Tai VW, et al.: Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000;23:35-43.
6. El-Sadr W, Reiss P, De Wit S, et al.: Relationship between prolonged exposure to combination ART and myocardial infarction: Effect of sex, age, and lipid changes. Abstract presented at the 12th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February 22-25, 2005.
7. UNAIDS, 2006 Report on the Global AIDS Epidemic. Available at http://www.unaids.org/en/HIV_data/2006GlobalReport/default.asp, accessed on January 10, 2007.
8. WHO Report. HIV/AIDS in Asia and the Pacific region 2003. Available at http://www.who.int; accessed on January 10, 2007.
9. Carr A and Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-1430.
10. Shevitz A, Wanke CA, Falutz J, and Kotler DP: Clinical perspectives on HIV-associated lipodystrophy syndrome: An update. AIDS 2001;15:1917-1930.
11. White AJ: Mitochondrial toxicity and HIV therapy. Sex Transm Infect 2001;77:158-173.
12. HIV Lipodystrophy Case Definition Study Group: An objective case definition of lipodystrophy in HIV-infected adults: A case-control study. Lancet 2003;361:726-735.
13. Hadigan C, Miller K, Corcoran C, Anderson E, Basgoz N, and Grinspoon S: Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women. J Clin Endocrinol Metab 1999;84:1932-1937.
14. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2004;27(Suppl. 1):S5-S10.
15. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 2001;285:2486-2497.
16. Kanabus A and Fredriksson J: HIV & AIDS in Thailand. Available at http://www.avert.org/aidsthai.htm; accessed on December 15, 2006.
17. Puttawong S, Prasithsirikul W, and Vadcharavivad S: Prevalence of lipodystrophy in Thai-HIV infected patients. J Med Assoc Thai 2004;87(6):605-611.
18. Paton NL, Earnest A, Ng YM, Karim F, and Aboulhab J: Lipodystrophy in a cohort of human immunodeficiency virus-infected Asian patients: Prevalence, associated factors, and psychological impact. Clin Infect Dis 2002;35:1244-1249.
19. Ho TT, Chan KC, Wong KH, and Lee SS: Indinavir-associated facial lipodystrophy in HIV-infected patients. AIDS Patients Care STDS 1999;13:11-16.
20. Fraser HE, Ishihara M, Miller JE, et al.: Prevalence survey of lipodystrophy in HIV-positive patients in Japan. In: Program and Abstracts of the 2nd International Workshop on Adverse Drug Reaction and Lipodystrophy, Toronto, September 13-15, 2000. International Medical Press, Singapore, 2000:12 [abstract 017].
21. Chang KH, Kim JM, Song YG, et al.: Does race protect an oriental population from developing lipodystrophy in HIV-treated individuals on HAART? J Infect 2002;44:33-38.
22. Saghayam S, Chaguturu SK, Kumarasamy N, et al.: Lipoatrophy is the predominant presentation of HIV-associated lipodystrophy in Southern India. Clin Infect Dis 2004;38:1646-1647.
23. Bacchetti P, Gripshover B, Grunfeld C, et al.: Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005;40(2):121-131.
24. Young J, Rickenbach M, Weber R, et al.: Body fat changes among antiretroviral-naive patients on PI- and NNRTI-based HAART in the Swiss HIV cohort study. Antiviral Ther 2005;10(1):73-81.
25. Cherry CL, Lal L, Thompson KA, et al.: Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from stavudine to abacavir or zidovudine. J Acquir Immune Defic Syndr 2005;38(3):263-267.
26. Shlay JC, Visnegarwala F, Bartsch G, et al.: Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). Body composition and metabolic changes in antiretroviral-naive patients randomized to didanosine and stavudine vs. abacavir and lamivudine. J Acquir Immune Defic Syndr 2005;38(2):147-155.
27. Martin A, Smith D, Carr A, et al., PIILR Study Group: Progression of lipodystrophy (LD) with continued thymidine analogue usage: Long-term follow-up from a randomized clinical trial (the PIILR study). HIV Clin Trials 2004;5(4):192-200.
28. Aekplakorn W, Stolk RP, Neal B, et al., for The InterAsia Collaborative Group: The prevalence and management of diabetes in Thai Adults. Diabetes Care 2003;26:2758-2763.
29. Riddler SA, Smit E, Cole SR, et al.: Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289:2978-2982.